![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 27, 25403-25408, July 8, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IIb
3 Inhibits Platelet Aggregation and Adhesion*



From the Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, 22 Hankou Road, Nanjing 210093, China
Activation or ligand binding induces conformational changes in
IIb
3, resulting in exposure of neoepitopes
named ligand-induced binding sites. We reported here a novel monoclonal
antibody developed by using Chinese hamster ovary (CHO) cells expressing an
activated
IIb
3 mutant (CHO
IIb
3
717) as the immunogen. This
IgG2b
named 3C7 was specific for the complex of
IIb
3 as demonstrated by flow cytometry,
immunoprecipitation, and EDTA chelating. The binding of 3C7 to platelets
increased significantly when platelets were activated by ADP/thrombin or
occupied by RGDS peptides, fibrinogen, or PAC-1, suggesting that 3C7 was an
anti-ligand-induced binding site antibody. The antibody failed to bind to the
CHO cells expressing another
IIb
3 mutant
(
3Y178A) suggesting that the
Cys177Cys184 loop of
3 was
likely the epitope for 3C7. 3C7 inhibited platelet aggregation, which was
initiated by ADP or thrombin in a dose-dependent manner (IC50s of
5.6 and 0.05 µg/ml, respectively). The antibody also inhibited platelet
adhesion to immobilized fibrinogen but not to fibronectin or collagen. These
findings suggested that 3C7 was a potent antagonist of integrin
IIb
3 and a potential anti-thrombotic
agent.
Received for publication, January 13, 2005 , and in revised form, May 12, 2005.
* This work was supported by Nanjing University (985-FZS, 20021201, and 20020284025) and by Jiangsu Kejiting (BG2000001 and BK2002082). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this paper.
To whom correspondence should be addressed: Institute of Molecular Medicine
and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University,
22 Hankou Rd., Nanjing 210093, China. Tel.: 86-25-8359-5678; Fax:
86-25-8326-0284; E-mail:
jnliu{at}verizon.net.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |